Study Of SB-683699 Compared To Placebo In Subjects With Relapsing-Remitting Multiple Sclerosis (MS)
Status:
Completed
Trial end date:
2010-08-01
Target enrollment:
Participant gender:
Summary
SB-683699 is an oral medication that is thought to reduce the number of active white blood
cells entering the brain; these white blood cells are part of the disease process for MS.
This study will look at whether different doses of SB-683699 are effective and safe in
patients with relapsing remitting MS.